AnGes was due to sit down with the US Food and Drug Administration on July 16 for a Pre-BLA Meeting, the customary checkpoint before filing a Biologics License Application. It will not happen. Written questions the Tokyo-listed biotech sent ahead of the session drew what it calls sufficiently positive answers from the FDA, and regulators told AnGes they had no issue with its planned rolling submission or the content of the filing materials. That made the meeting redundant, and AnGes says it is now proceeding straight into BLA submission procedures.
The product at stake is HGF gene therapy, generic name beperminogene perplasmid, aimed at chronic limb-threatening ischemia (CLTI) in patients with peripheral artery disease. AnGes cites outcomes data to frame the stakes: five-year mortality after a major leg amputation runs at 57%, a figure the company says trails only lung cancer's 80% among the comparisons drawn by Armstrong and colleagues. The company argues earlier-stage treatment can extend the time patients go without ulcers or amputation.
This is the latest step in a filing sequence AnGes has been laying out since August 2025, when it decided to complete clinical work and prepare a BLA after securing an active-ingredient supply deal with Boehringer Ingelheim Biopharmaceuticals. Type B meetings on clinical and manufacturing-quality matters followed in January and May 2026, each ending in what AnGes described as FDA agreement on its filing approach.
What changed here is procedural, not predictive: the FDA has signed off on AnGes's rolling-submission plan and the shape of its dossier, not on the therapy itself. AnGes says cancelling the meeting has no effect on its consolidated financial results.